Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline Pharmaceuticals Limited ( (IN:GLAXO) ) just unveiled an announcement.
GlaxoSmithKline Pharmaceuticals Limited has announced that its board has approved the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. Biswas, a veteran GSK finance executive with over 25 years of global experience across India, Vietnam, Singapore, Brazil, and the UK, brings deep expertise in financial reporting, performance management, and internal controls.
The current CFO, Juby Chandy, will step down as Whole-Time Director and CFO effective March 11, 2026, following his promotion to lead APAC Finance within the wider GSK group. The company has credited Chandy with strengthening its financial position, improving governance, and executing key transformation priorities, signaling a continuity-focused leadership transition that may support stable financial stewardship and reinforce GSK’s governance standards in India.
More about GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is an India-based pharmaceutical company focused on developing, manufacturing, and marketing prescription medicines and vaccines. Operating as part of the global GSK group, it serves the domestic Indian market while aligning with international standards in healthcare and life sciences.
Average Trading Volume: 4,882
Technical Sentiment Signal: Buy
Current Market Cap: 435.4B INR
For detailed information about GLAXO stock, go to TipRanks’ Stock Analysis page.